Role of bromelain in the treatment of patients with pityriasis lichenoides chronica

Journal of Dermatological Treatment

Volumn 18, Issue 4, 2007, Pages 219-222

  Massimiliano, Risulo ^a   Pietro, Rubegni ^a,b   Paolo, Sbano ^a   Sara, Poggiali ^a   Michele, Fimiani ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Bromelain; Pityriasis lichenoides; Pityriasis lichenoides chronica

Indexed keywords

BROMELAIN; DOXYCYCLINE; ERYTHROMYCIN; METHYLPREDNISOLONE; MINOCYCLINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTRITIS; GASTROINTESTINAL SYMPTOM; HISTOLOGY; HUMAN; LOW DRUG DOSE; MALE; PHOTOTHERAPY; PINEAPPLE; PITYRIASIS LICHENOIDES; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; BROMELAINS; CHRONIC DISEASE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PITYRIASIS LICHENOIDES; SKIN; TREATMENT OUTCOME;

EID: 34547617866     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701299147     Document Type: Article

References (25)

1. Patel DG, Kihicza KG, Schawartz RA, Janniger CK, Lambert C. Pityriasis lichenoides. Cutis. 2000;65:17-23.
2. Tomasini D, Tomasini CF, Cerri A, Sangalli G, Palmeto G, Hantschke M, et al. Pityriasis lichenoides: A cytotoxic T-cell-mediated skin disorder. Evidence of human parvovirus B19 DNA in nine cases. J Cutan Pathol. 2004;31:531-8.
3. Magro C, Crowson AN, Kovatich A, Burns F. Pityriasis lichenoides: A clonal T-cell lymphoproliferative disorder. Hum Pathol. 2002;33:788-94.
4. Labarthe MP, Salomon D, Saurat JH. Ulcération linguales, parapsoriasis en gouttes et primo-infection a parvovirus B19. Ann Dermatol Venereol. 1996;123:735-8.
5. Weinberg JM, Kristal L, Chooback L, Honig PJ, Kramer EM, Lessin SR. The clonal nature of pityriasis lichenoides. Arch Dermatol. 2002;138:1063-7.
6. Maurer HR. Bromelain: Biochemistry, pharmacology and medical use. Cell Mol Life Sci. 2001;58:1234-45.
7. Kane S, Goldberg MJ. Use of bromelain for mild ulcerative colitis. Ann Intern Med. 2000;132:680.
8. Hale LP, Greer PK, Trinh CT, Gottfried MR. Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease. Clin Immunol. 2005;116:135-42.
9. Weichert WS, Parker JSL, Wahid ATM, Chang SF, Meier E, Parrish CR. Assaying for structural variation in the parvovirus capsid and its role in infection. Virology. 1998;250:106-17.
10. Panse I, Bourrat E, Rybojad M, Morel P. Photochemotherapy for pityriasis lichenoides: 3 cases. Ann Dermatol Venereol. 2004;131:201-3.
11. Calzavara Pinton P, Capezzera R, Zane C, De Panfilis G. Medium-dose ultraviolet A1 therapy for pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica. J Am Acad Dermatol. 2002;47:410-14.
12. Piamphongsant T. Tetracycline for the treatment of pityriasis lichenoides. Br J Dermatol. 1974;91:319-22.
13. Lynch PJ, Saied NK. Methotrexate treatment of pityriasis lichenoides and lymphomatoid papulosis. Cutis. 1979;23:634-6.
14. Khachemoune A, Blyumin ML. Pityriasis lichenoides: pathophysiology, classification, and treatment. Am J Clin Dermatol. 2007;8:29-36.
15. Gupta AK, Ellis CN, Nickoloff BJ, Goldfarb MT, Ho VC, Rocher LL, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol. 1990;126:339-50.
16. Simon D, Boudny C, Nievergelt H, Simon HU, Braathen LR. Successful treatment of pityriasis lichenoides with topical tacrolimus. Br J Dermatol. 2004;150:1033-5.
17. Gaciong Z, Paczek L, Bojakowski K, Socha K, Wisniewski M, Heidland A. Beneficial effect of proteases on allograft arteriosclerosis in a rat aortic model. Nephrol Dial Transplant. 1996;11:987-9.
18. Targoni OS, Tary-Lehmann M, Lehmann PV. Prevention of murine EAE by oral hydrolytic enzyme treatment. J Autoimmun. 1999;12:191-8.
19. Thornhill SM, Kelly AM. Natural treatment of perennial allergic rhinitis. Altern Med Rev. 2000;5:448-54.
20. Rovenska E, Svik K, Stancikova M, Rovensky J. Inhibitory effect of enzyme therapy and combination therapy with cyclosporin A on collagen-induced arthritis. Clin Exp Rheumatol. 2001;19:303-9.
21. Majima M, Nishiyama K, Iguchi Y, Yao K, Ogino M, Ohno T, et al. Determination of bradykinin-(1-5) in inflammatory exudate by a new ELISA as a reliable indicator of bradykinin generation. Inflamm Res. 1996;45:416-23.
22. Ogino M, Majima M, Kawamura M, Hatanaka K, Saito M, Harada Y, et al. Increased migration of neutrophils to granulocyte-colony stimulating factor in rat carrageenan-induced pleurisy: Roles of complement, bradykinin, and inducible cyclooxygenase-2. Inflamm Res. 1996;45:335-46.
23. Inoue K, Motonaga A, Dainaka J, Nishimura T, Hashii H, Yamate K, et al. Effect of etodolac on prostaglandin E2 biosynthesis, active oxygen generation and bradykinin formation. Prostaglandins Leukot Essent Fatty Acids. 1994;51:457-62.
24. Wittenborg A, Bock PR, Hanisch J, Saller R, Schneider B. Comparative epidemiological study in patients with rheumatic diseases illustrated in an example of a treatment with non-steroidal anti-inflammatory drugs versus an oral enzyme combination preparation. Arzneimittelforschung. 2000;50:728-38.
25. Masson M. Bromelain in blunt injuries of the locomotor system. A study of observed applications in general practice. Fortschr Med. 1995;113:303-6.